| Tazobactam (sodium salt)β-lactamases inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Tazobactam (sodium salt) Dilution Calculator
calculate
Tazobactam (sodium salt) Molarity Calculator
calculate
| Cas No. | 89785-84-2 | SDF | Download SDF |
| Synonyms | CL-307579,YTR 830 | ||
| Chemical Name | 4,4-dioxide 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, monosodium salt | ||
| Canonical SMILES | O=C(C1)N2[C@]1([H])S([C@](CN3C=CN=N3)(C)[C@@H]2C([O-])=O)(=O)=O.[Na+] | ||
| Formula | C10H11N4O5S • Na | M.Wt | 322.3 |
| Solubility | ≥32.2mg/mL in H2O | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Tazobactam is a β-lactamase inhibitor [1]. Tazobactam shows intrinsic activity against Acinetobacter strains.
The β-Lactamases are responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome β-lactamase-mediated resistance, β-lactamase inhibitors have been introduced into clinical practice [2].
Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against 29 of the 38 strains [1]. Tazobactam in combination with the ureidopenicillin, piperacillin successfully restored the activity of piperacillin against β-lactamase-producing bacteria [3]. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases [3]. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes [3].
Preliminary clinical data indicated that the fixed combination of piperacillin /tazobactam was effective in the treatment of moderate to severe polymicrobial infections, including skin, intra-abdominal and soft-tissue and lower respiratory tract infections [3]. Piperacillin/tazobactam in combination with an aminoglycoside was effective in the empirical treatment of fever in patients with neutropenia. In phase III trials, piperacillin/tazobactam showed a tolerability profile typical of a penicillin agent [3].
References:[1] Higgins P G, Wisplinghoff H, Stefanik D, et al. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J]. Antimicrobial agents and chemotherapy, 2004, 48(5): 1586-1592.[2] Drawz S M, Bonomo R A. Three decades of β-lactamase inhibitors[J]. Clinical microbiology reviews, 2010, 23(1): 160-201.[3] Perry C M, Markham A. Piperacillin/tazobactam[J]. Drugs, 1999, 57(5): 805-843.
